Diabetic macular oedema is a major cause of severe visual loss whose pathogenesis appears to be complex and multifactorial. For many years laser photocoagulation has been the standard of care for the treatment of this condition. Emerging pharmacologic approaches are being evaluated through randomised controlled trials. Triamcinolone acetonide has been proposed as a promising option, due to its well-known anti-inflammatory, anti-permeability and anti-angiogenic properties. Intravitreal delivery allows bypassing of the blood-retinal barrier to achieve a more concentrated dose of steroid in the vitreal cavity for a prolonged time. Intravitreal triamcinolone acetonide is effective in reducing central macular thickness and improving visual acuity, even if the duration of action is often provisional and requires repeated injections. Drug-related and injection-related side effects have been reported; the most common are induced cataract and increased intraocular pressure. To extend the duration of steroid effects and to minimise the risk of complications, alternative routes of administration and extend-release implants are being investigated.
Triamcinolone acetonide (TA) is a synthetic steroid of the glucocorticoid family with a fluorine in the ninth position. 1 It is commercially available as an ester and represents one of the most commonly used steroid agents for the treatment of several retinal conditions. 2 TA has an anti-inflammatory potency five times higher than hydrocortisone with a 10th of the sodium-retaining potency. It appears as a white-to cream-colored crystalline powder and it is practically insoluble in water and very soluble in alcohol. 3 The decreased water solubility accounts for its prolonged duration of action. It has been observed that adequate concentrations of TA could provide therapeutic effects for approximately three months after 4 mg intravitreal TA injection. 4 A maximum effect duration of 140 days has been suggested. 5, 6 Mechanism TA has been shown to inhibit the inflammatory response, thereby reducing oedema formation, leukocyte migration, capillary dilatation and fibroblast proliferation. Steroids are thought to act by the induction of proteins called lipocortins, in particular phospholipase A2. These proteins reduce leukocyte chemotaxis, control biosynthesis and inhibit the release of arachidonic acid from the phospholipid membrane, which is one of the most important common precursors of potent inflammatory cell mediators such as prostaglandins and leukotrienes. 8 The anti-inflammatory, angiostatic and anti-permeability proprieties of corticosteroids seem also to be related to the regulation of gene expression components. This regulation influences the expression of vascular endothelial growth factor (VEGF), inhibits pro-inflammatory genes such as tumour necrosis factor-alpha (TNF-α) and other inflammatory chemokines, and induces the expression of anti-inflammatory factors such as pigment epithelium-derived factor (PEDF). [9] [10] [11] Some studies show that TA, at therapeutic concentrations, significantly inhibits the expression of TNF-α, interleukin 1-beta (IL-1β), thromboxane B2
(TxB2) and leukotriene B4 (LTB4), in a dose-dependent manner. 12 Additionally, TA seems to reduce the expression of matrix metalloproteinases (MMPs) and to downregulate intercellular adhesion molecule 1 (ICAM-1) on choroidal endothelial cells.
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Efficacy of Intravitreal Triamcinolone Acetonide
Based on several studies, intravitreal administration of TA has provided promising results for the treatment of disorders associated with an abnormal endothelial cell proliferation and conditions complicated by intra-retinal and subretinal fluid accumulation. The anti-inflammatory, angiostatic and anti-permeability properties of TA have gained interest in chronic retinal diseases, such as diabetic macular oedema (DMO). [14] [15] [16] [17] [18] DMO is the leading cause of vision loss in the working-age population and it occurs as an increased accumulation of fluid within the intra-retinal layers of the macula as a result of retinal microvascular changes and disruption of the blood-retinal barrier. The rationale for using a steroidal drug for the treatment of oedematous and proliferative diseases is that abnormal proliferation of cells is often associated with and trigged by inflammation and intra-retinal accumulation of fluid is usually accompanied by a blood-retinal barrier dysfunction that can be restored with steroid therapy. 19 Intravitreal TA has been widely studied in many randomised clinical trials on DMO demonstrating significant improvements both in morphological and functional outcomes.
However, a substantial group of patients are unresponsive to laser therapy and fail to improve after photocoagulation. It has been reported that three years after initial grid treatment visual acuity improved in 14. Triamcinolone Acetonide for the Treatment of Diabetic Macular Oedema 
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Post-injection Infectious Endophthalmitis
Infectious endophthalmitis is one of the most serious complications of intravitreal injection of TA, with the reported risk per injection ranging from 0.1 % to 1.6 %. 57 Many studies suggest that this relatively high rate of infectious endophthalmitis may be attributed to the techniques used for injection. If the injection is performed under sterile conditions, the risk of an infection may be lower. [58] [59] [60] [61] [62] [63] [64] [65] Patients with infectious endophthalmitis after intravitreal TA usually present without pain, which is uncommon for infectious endophthalmitis in eyes without intraocular steroids. 66 
Post-injection Pseudoendophthalmitis
Several studies have described non-infectious endophthalmitis after intravitreal injection of TA. 
Toxic Effects
Previous studies in rabbits found that preservatives in the vehicle for suspension of crystalline steroids, rather than steroid itself, could be toxic to the rabbit retina and lens and that the vehicle is not totally responsible for the toxicity, but may initiate TA-dependent toxicity. 90, 91 Direct toxic effects of TA on the retina and optic nerve have not yet been observed, independently of the dose used. 92 TA has been shown to be toxic to retinal pigment epithelial cells in vitro, 93 whereas ex vivo 94 and in vivo 95 studies have failed to show any significant toxicity to the retina. Because TA is a heavy depot formulated suspension, it settles in the inferior vitreous cavity. Whereas there is certainly distribution of the drug throughout the vitreous cavity due to diffusion and constant eye movements, it is possible that the drug does not distribute equally in the vitreous cavity and that the concentration of the drug at the macula is different (presumably lower) than in the inferior retinal periphery. 96 Yeung et al. reported a possible cytotoxic effect of TA, causing a significant reduction in cell numbers throughout the whole range of concentrations when retinal pigment epithelium cells were exposed to it for more than one day. 97 Compared with dexamethasone and hydrocortisone, TA showed the higher relative toxicity.
Safety of Intravitreal Triamcinolone Acetonide Including High-dose Reinjections
In a case series study, Gilles et al. showed that side effects or complications may not occur more frequently after reinjections of TA than after a primary intravitreal high-dose injection. 81 Moreover, the intravitreal high-dose reinjections may be tolerated by eyes within a mean follow-up of about 21 months after the first injection, or about 10 months after the last injection and the increase in IOP may not be more marked after a repeated injection than after the first injection.
Systemic Safety
In the randomised study from DRCR.net comparing laser photocoagulation with ranibizumab in combination with laser and intravitreal TA associated with laser, no evidence suggests that the administration of TA is associated with an increased risk of systemic adverse events, including stroke or cardiac events. Two-year incidence of non-fatal myocardial infarction was 3 % in the laser alone group, 1 % in the ranibizumab-laser group and 3 % in the TA-laser group. Any cardiovascular event, as defined by the Antiplatelet Trialists' Collaboration (ATC), occurred in 12 % of the laser alone group, 5 % of the ranibizumab-laser group and 6 % of the TA-laser group.
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Triamcinolone Acetonide for the Treatment of Diabetic Macular Oedema In this study laser photocoagulation appeared safer and more effective than the combination of intravitreal injection of TA and laser treatment.
However, when considering patients that were pseudophakic at baseline, TA in combination with laser resulted in better visual outcomes than laser alone. The results of the combination of TA and laser were comparable to those obtained with the combination of laser and ranibizumab in this subgroup of patients after two years of follow-up. 31 The rationale for combining laser photocoagulation and intravitreal TA lies in their synergistic mechanism of action and may offer the chance to reduce the number of intravitreal injections required and so decrease the rate of drug-and injection-related adverse events. However, several vision-threatening side effects have been reported as a result of thermal damage caused by laser procedure. [98] [99] [100] In recent years advances in laser therapy of retinal diseases have been directed at reducing the unnecessary disruptive effect that laser photocoagulation produces in retinal tissues.
Several studies have shown the efficacy of sub-threshold laser photocoagulation in treating DMO, producing fewer side effects than conventional laser treatment. [101] [102] [103] [104] [105] Combining intravitreal TA and sub-threshold laser photocoagulation may be a promising option to obtain good and durable visual outcomes while reducing the side effects correlated to either the laser procedure or the drug.
Many questions still remain unanswered concerning the optimal dose of TA for intravitreal use and the side-effect profiles of various commercially available formulations of TA with and without preservatives. Thus, an optimal balance between efficacy and safety profile has yet to be completely determined. Novel steroid implants and anti-VEGF drugs are being evaluated alone or in combination as promising options in the emerging armamentarium for the treatment of DMO. n Diabetic Macular Oedema
